
RMD
ResMed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 1
Dividend Princes
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RMD
Resmed Inc.
A leading developer and manufacturer of medical devices for sleep-disordered breathing and respiratory care
Healthcare Equipment and Supplies
Invalid Date
09/30/1999
New York Stock Exchange
10,140
06-30
Common stock
9001 Spectrum Center Blvd., San Diego, CA 92123, United States of America
Medical device manufacturing
ResMed Inc., a Delaware corporation, was founded in March 1994. The company is a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory diseases, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular diseases and other chronic diseases. The company's products and solutions are designed to improve patients' quality of life, reduce the impact of chronic diseases, and reduce health care costs as the global health care system continues to drive the transfer of care from hospitals to homes and low-cost environments. The company's cloud-based digital software health applications, as well as devices, are designed to provide connected care to improve patient outcomes and increase customer efficiency.
Company Financials
EPS
RMD has released its 2025 Q3 earnings. EPS was reported at 2.37, versus the expected 2.36, beating expectations. The chart below visualizes how RMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RMD has released its 2025 Q3 earnings report, with revenue of 1.29B, reflecting a YoY change of 7.92%, and net profit of 365.04M, showing a YoY change of 21.48%. The Sankey diagram below clearly presents RMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available